B7-Positive and B7-Negative Acute Myeloid Leukemias Display Distinct T Cell Maturation Profiles, Immune Checkpoint...

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Acute myeloid leukemia (AML) is often considered poorly immunogenic, leading to T cell tolerance.
• However, the immune landscape of AML is heterogeneous, with varying B7 checkpoint ligand expression.
• B7 expression is linked to an interferon-mediated inflammatory phenotype.

Purpose of the Study:

• To investigate the expression of B7 checkpoint ligands and their receptors on AML blasts and bone marrow T cells.
• To identify distinct immune profiles within AML based on B7 expression patterns.
• To explore the implications of these profiles for targeted immunotherapies.

Main Methods:

• Flow cytometry was used to analyze B7 checkpoint ligands (B7.1, B7.2, PD-L1, PD-L2, ICOS-L, B7-H3, B7-H4) on AML blasts.
• Expression of corresponding receptors (CTLA-4, PD-1, ICOS) was assessed on bone marrow T cell populations.
• Thirty newly diagnosed AML patients were included in the study.

Main Results:

• Two distinct groups of AML were identified: B7-negative and B7-positive leukemias.
• B7-positive AMLs showed intermediate/adverse European Leukemia Net (ELN) risk and specific T cell populations (memory CD4+, effector CD8+).
• B7-negative AMLs, including NPM1-mutated cases, displayed different T cell profiles and B7-H3 expression.

Conclusions:

• AML exhibits diverse B7 immune profiles, indicating varied immune evasion strategies.
• These distinct profiles necessitate the development of specific immunotherapies for AML.
• Understanding the immune landscape is crucial for advancing AML treatment.